Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long‐Term Clinical Outcomes and Stent Thrombosis of Sirolimus‐Eluting Versus Bare Metal Stents in Patients with End‐Stage Renal Disease: Results of Korean Multicenter Angioplasty Team (KOMATE) Registry

Long‐Term Clinical Outcomes and Stent Thrombosis of Sirolimus‐Eluting Versus Bare Metal Stents in... Background: There are still controversies about long‐term clinical outcomes of sirolimus‐eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end‐stage renal diseases (ESRD). Objective: To compare long‐term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation (SES‐ESRD) were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods (BMS‐ESRD) in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3‐year follow‐up. Results: The cumulative 3‐year rate of composite of death, MI, or ST of the SES‐ESRD group (24%) was nearly similar with that of the BMS‐ESRD group (24%, P = 1.000). The 3‐year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES‐ESRD did not differ significantly from those in the BMS‐ESRD. However, the SES‐ESRD showed a sustained lower 3‐year TVR rate (9%), compared with BMS‐ESRD (24%, P = 0.042). The rate of any ST in SES‐ESRD was not significantly higher than that in the BMS‐ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES‐ESRD (15%) versus BMS‐ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long‐term follow‐up, compared with BMS. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Long‐Term Clinical Outcomes and Stent Thrombosis of Sirolimus‐Eluting Versus Bare Metal Stents in Patients with End‐Stage Renal Disease: Results of Korean Multicenter Angioplasty Team (KOMATE) Registry

Download PDF
9 pages

Loading next page...
 
/lp/wiley/long-term-clinical-outcomes-and-stent-thrombosis-of-sirolimus-eluting-8NoI75JvHb

References (21)

Publisher
Wiley
Copyright
©2009, the Authors Journal compilation ©2009, Wiley Periodicals, Inc.
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2009.00495.x
pmid
19702679
Publisher site
See Article on Publisher Site

Abstract

Background: There are still controversies about long‐term clinical outcomes of sirolimus‐eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end‐stage renal diseases (ESRD). Objective: To compare long‐term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation (SES‐ESRD) were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods (BMS‐ESRD) in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3‐year follow‐up. Results: The cumulative 3‐year rate of composite of death, MI, or ST of the SES‐ESRD group (24%) was nearly similar with that of the BMS‐ESRD group (24%, P = 1.000). The 3‐year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES‐ESRD did not differ significantly from those in the BMS‐ESRD. However, the SES‐ESRD showed a sustained lower 3‐year TVR rate (9%), compared with BMS‐ESRD (24%, P = 0.042). The rate of any ST in SES‐ESRD was not significantly higher than that in the BMS‐ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES‐ESRD (15%) versus BMS‐ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long‐term follow‐up, compared with BMS.

Journal

Journal of Interventional Cardiology – Wiley

Published: Oct 1, 2009

There are no references for this article.